Ipsen SA, of Paris, reported phase IIa results showing that Dysport was associated with a mean reduction from baseline of urinary incontinence episodes greater than 75 percent, 12 weeks after injection, regardless of how the drug was administered in patients with urinary incontinence not adequately managed by anticholinergics.